60 Degrees Pharmaceuticals Announces Clinical and Molecular Results for Babesiosis Study

60 Degrees Pharmaceuticals Announces Investor Webinar on Tafenoquine Development and ARAKODA Commercialization

60 Degrees Pharmaceuticals, Inc. will host an investor webinar on November 10, 2026, to discuss its clinical progress in babesiosis and commercial expansion of its malaria prevention drug, ARAKODA.

60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine

60 Degrees Pharmaceuticals has entered into a sponsored research agreement with The University of Southern Mississippi to assess the therapeutic potential of castanospermine in nonclinical models of alpha-gal syndrome.

60 Degrees Pharma shares are trading lower after the company announced its plans to conclude enrollment in its severe babesiosis study at 30 patients and unblind the trial, with final results expected in January 2027.

60 Degrees Pharmaceuticals Will Conclude Enrollment In Study Of Tafenoquine In Patients Hospitalized With Severe Babesiosis And Proceed With Unblinding; Primary And Secondary Endpoint Results Are Expected In January 2027

After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blindedAs of the

60 Degrees Pharmaceuticals To Present Data On Interim Analysis From Its Clinical Trial Of Tafenoquine On Oct. 6

60 Degrees Pharmaceuticals Says It Submitted Statement Of Interest To FDA For Commissioner's National Priority Voucher For ARAKODA In Babesiosis; DSMB Interim Analysis Of Phase 2 Trial Scheduled October 1, Targets sNDA Submission In March-April 2027

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001946563/000121390026099702/ea0305442-8k_60degree.htm